MSB Medical School Berlin, Hochschule für Gesundheit und Medizin, Berlin, Germany.
Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Blood Cancer J. 2024 Aug 20;14(1):140. doi: 10.1038/s41408-024-01121-8.
Genome-wide association studies (GWASs) based on common single nucleotide polymorphisms (SNPs) have identified several loci associated with the risk of monoclonal gammopathy of unknown significance (MGUS), a precursor condition for multiple myeloma (MM). We hypothesized that analyzing haplotypes might be more useful than analyzing individual SNPs, as it could identify functional chromosomal units that collectively contribute to MGUS risk. To test this hypothesis, we used data from our previous GWAS on 992 MGUS cases and 2910 controls from three European populations. We identified 23 haplotypes that were associated with the risk of MGUS at the genome-wide significance level (p < 5 × 10) and showed consistent results among all three populations. In 10 genomic regions, strong promoter, enhancer and regulatory element-related histone marks and their connections to target genes as well as genome segmentation data supported the importance of these regions in MGUS susceptibility. Several associated haplotypes affected pathways important for MM cell survival such as ubiquitin-proteasome system (RNF186, OTUD3), PI3K/AKT/mTOR (HINT3), innate immunity (SEC14L1, ZBP1), cell death regulation (BID) and NOTCH signaling (RBPJ). These pathways are important current therapeutic targets for MM, which may highlight the advantage of the haplotype approach homing to functional units.
全基因组关联研究(GWAS)基于常见的单核苷酸多态性(SNP),已经确定了几个与单克隆丙种球蛋白病(MGUS)风险相关的位点,MGUS 是多发性骨髓瘤(MM)的前驱状态。我们假设,分析单倍型可能比分析单个 SNP 更有用,因为它可以识别出共同导致 MGUS 风险的功能染色体单元。为了验证这一假设,我们使用了来自三个欧洲人群的 992 例 MGUS 病例和 2910 例对照的先前 GWAS 数据。我们确定了 23 个单倍型,它们在全基因组显著水平(p<5×10)与 MGUS 风险相关,并且在所有三个人群中均显示出一致的结果。在 10 个基因组区域中,强烈的启动子、增强子和调节元件相关的组蛋白标记及其与靶基因的连接,以及基因组分割数据,支持了这些区域在 MGUS 易感性中的重要性。几个相关的单倍型影响了对 MM 细胞存活很重要的途径,如泛素-蛋白酶体系统(RNF186、OTUD3)、PI3K/AKT/mTOR(HINT3)、先天免疫(SEC14L1、ZBP1)、细胞死亡调节(BID)和 NOTCH 信号(RBPJ)。这些途径是 MM 的当前重要治疗靶点,这可能突出了单倍型方法对功能单元的优势。